← ANALYST RATINGS · TIPRANKS
Ascendis Pharma (ASND): analyst forecast and price target
Analyst consensus
Strong Buy19 Buy0 Hold0 Sell
Ratings of 19 analysts in the last 3 months12-month forecast
Based on 19 price targets given in the last 3 months, the average target is $315, the highest $360, the lowest $269. The average is +40.0% from the last price of $225.
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $307 → $269−12.4% | Buy | +19.4% | Reiterated | 14.10.26on TipRanks 19:50 | −0.5%next day +0.5% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $273 | Buy | +21.2% | Assigned | 12.10.26on TipRanks 08:15 | −0.9%next day −1.7% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | — | Buy | — | Reiterated | 10.10.26on TipRanks Oct 12 05:10 | −0.9%next day −1.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $267 → $248−7.1% | Buy | +10.1% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $260 → $242−6.9% | Hold | +7.4% | Downgrade | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $261 → $243−6.9% | Hold | +7.9% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $249 → $232−6.8% | Hold | +3.0% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $275 → $255−7.3% | Buy | +13.2% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $273 → $254−7.0% | Buy | +12.8% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Reiterated | 09.10.26on TipRanks 06:15 | +2.3%next day −0.9% · 5 days +0.2% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $290 | Buy | +28.7% | Reiterated | 08.10.26on TipRanks 21:45 | +2.3%next day −0.9% · 5 days +0.2% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $273 | Buy | +21.2% | Assigned | 02.10.26on TipRanks Oct 3 13:30 | −0.5%next day −0.6% · 5 days −0.6% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $329 | Buy | +46.1% | Reiterated | 30.09.26on TipRanks 05:25 | +0.1%next day −0.4% · 5 days −1.7% | ↗ |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | $300 | Buy | +33.2% | Reiterated | 25.09.26on TipRanks Sep 28 08:30 | −2.8%next day +2.7% · 5 days +1.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $281 → $267−5.0% | Buy | +18.5% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $280 → $260−7.1% | Hold | +15.4% | Downgrade | 16.09.26on TipRanks 13:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $271 → $261−3.7% | Hold | +15.9% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $260 → $249−4.2% | Hold | +10.5% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $287 → $275−4.2% | Buy | +22.1% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $279 → $273−2.2% | Buy | +21.2% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $327 | Buy | +45.2% | Reiterated | 16.09.26on TipRanks 07:15 | +3.7%next day −4.6% · 5 days −12.0% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $344 | Buy | +52.7% | Reiterated | 16.09.26on TipRanks 06:25 | +3.7%next day −4.6% · 5 days −12.0% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $304 | Buy | +35.0% | Reiterated | 15.09.26on TipRanks Sep 16 04:55 | −9.0%next day +3.7% · 5 days −3.3% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | — | Buy | — | Reiterated | 15.09.26on TipRanks 13:21 | −9.0%next day +3.7% · 5 days −3.3% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $287 | Buy | +27.4% | Reiterated | 15.09.26on TipRanks 05:50 | −9.0%next day +3.7% · 5 days −3.3% | ↗ |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $319 | Buy | +41.6% | Reiterated | 14.09.26on TipRanks Sep 15 10:25 | +1.0%next day −9.0% · 5 days −12.2% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $304 → $312+2.6% | Buy | +38.5% | Reiterated | 02.09.26on TipRanks 08:30 | +2.3%next day +0.4% · 5 days −1.3% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $326 | Buy | +44.7% | Reiterated | 01.09.26on TipRanks 22:05 | +2.3%next day +0.4% · 5 days −1.3% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $333 → $330−0.9% | Buy | +46.5% | Reiterated | 31.08.26on TipRanks 09:10 | +6.4%next day −0.4% · 5 days +2.8% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $326 | Buy | +44.7% | Reiterated | 14.08.26on TipRanks 06:55 | +1.1%next day 0.0% · 5 days +3.3% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $355 → $360+1.4% | Buy | +59.8% | Reiterated | 14.08.26on TipRanks 02:30 | +1.1%next day 0.0% · 5 days +3.3% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $280 → $290+3.6% | Buy | +28.7% | Reiterated | 13.08.26on TipRanks Aug 14 08:35 | −4.3%next day +1.1% · 5 days +5.4% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $325 → $341+4.9% | Buy | +51.4% | Reiterated | 13.08.26on TipRanks 23:50 | +1.1%next day 0.0% · 5 days +3.3% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $329 | Buy | +46.1% | Reiterated | 07.08.26on TipRanks 13:07 | +1.6%next day +0.1% · 5 days −3.1% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $260 → $300+15.4% | Buy | +33.2% | Reiterated | 27.07.26on TipRanks 14:08 | −0.2%next day +0.2% · 5 days −6.4% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $305 | Buy | +35.4% | Reiterated | 02.06.26on TipRanks Jun 4 22:00 | −1.1%next day +0.8% · 5 days +1.4% | ↗ |
| Unknown Analyst | Wolfe Research | $255 | Buy | +13.2% | Initiated | 17.11.25on TipRanks 16:25 | +1.1%next day −2.7% · 5 days −7.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Ascendis Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 03.10.26: target $317 at a price of $228 (+39.3%); now: $315 at $225 (+40.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 32 | 26 | 27 | 37 | 47 | 46 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.90 (from $0.47 to $1.25). Last quarter: $3.18.
Sales
Next quarter’s sales estimate — $408M (from $354M to $455M). Last quarter: $394M.
Best top-analyst consensus in the sector · Healthcare
About Ascendis Pharma
- CEO: Jan Moller Mikkelsen
- Employees: 1,189
- Tuborg Boulevard 12, Hellerup, CR, 2900, DK
- ascendispharma.com
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Data from the stock’s TipRanks forecast page, read 35 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗